Literature DB >> 11019850

Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation.

Y Kishi1, M Kami, Y Oki, Y Kazuyama, M Kawabata, S Miyakoshi, S Morinaga, R Suzuki, S Mori, Y Muto.   

Abstract

We describe two patients who developed respiratory syncytial virus (RSV) pneumonia after BMT. One died of RSV pneumonia after three courses of steroid pulse therapy. Surprisingly, RSV antigen was identified in the bronchoalveolar lavage fluid (BALF) obtained post mortem. Steroid pulse therapy might have suppressed anti-RSV immunity, leading to persistent RSV infection for more than 1 month. The other patient received donor lymphocyte infusions (DLI) for relapsed plasma cell leukemia, while having active RSV pneumonia. His respiratory condition improved after DLI, and RSV antigen disappeared in BALF and nasal swabs. DLI might be effective in cases of life-threatening RSV pneumonia.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11019850     DOI： 10.1038/sj.bmt.1702559

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  9 in total

1.  A prospective surveillance of nosocomial respiratory syncytial virus infection in a hematology ward: a single-center experience in Japan.

Authors:  M Kami; Y Kishi; T Hamaki; Y Maruta; E Kusumi; H Iwata; J I Ueyama; S Miyakoshi; S I Morinaga; Y Mutou
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

2.  Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients.

Authors:  J Gozdzik; K Rewucka; A Krasowska-Kwiecien; A Pieczonka; R Debski; A Zaucha-Prazmo; K Drabko; J Krukowska-Jaros; M Wozniak; J Kowalczyk; M Wysocki; E Gorczynska; K Kalwak; A Chybicka; J Wachowiak
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

Review 3.  Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.

Authors:  Katherine A Baugh; Ifigeneia Tzannou; Ann M Leen
Journal:  Curr Opin Infect Dis       Date:  2018-08       Impact factor: 4.915

Review 4.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

Review 5.  Graft-versus-host disease after donor leukocyte infusions: presentation and management.

Authors:  Noelle V Frey; David L Porter
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

6.  Cellular therapy following allogeneic stem-cell transplantation.

Authors:  Alison Rager; David L Porter
Journal:  Ther Adv Hematol       Date:  2011-12

7.  Comparing the application of mNGS after combined pneumonia in hematologic patients receiving hematopoietic stem cell transplantation and chemotherapy: A retrospective analysis.

Authors:  Binglei Zhang; Ruirui Gui; Qian Wang; Xueli Jiao; Zhen Li; Juan Wang; Lu Han; Ling Zhou; Huili Wang; Xianjing Wang; Xinxin Fan; Xiaodong Lyu; Yongping Song; Jian Zhou
Journal:  Front Cell Infect Microbiol       Date:  2022-09-21       Impact factor: 6.073

Review 8.  Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.

Authors:  Cécile Pochon; Sebastian Voigt
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640

Review 9.  Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.

Authors:  Yoshiki Furukawa; Yasuharu Hamano; Shuichi Shirane; Shintaro Kinoshita; Yoko Azusawa; Jun Ando; Hiromitsu Nakauchi; Miki Ando
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.